AKT1 and neoplasm: The HIV-reverse transcriptase inhibitors zidovudine and lamivudine can downregulate MMP-9 expression in normal or tumor cells, weaken MAPK/ERK or PI3K/AKT phosphorylation, reduce nitric oxide production and impair angiogenesis [174,216,217,218].